Patents Assigned to United States of America, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 12043660Abstract: Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.Type: GrantFiled: December 14, 2021Date of Patent: July 23, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Trustees of Columbia University in the City of New YorkInventors: Peter Kwong, Young Do Kwon, Ivelin Georgiev, Gilad Ofek, Baoshan Zhang, Krisha McKee, John Mascola, Mark Connors, Gwo-Yu Chuang, Sijy O'Dell, Robert Bailer, Mark Louder, Mangaiarkarasi Asokan, Richard Schwartz, Jonathan Cooper, Kevin Carlton, Michael Bender, Amarendra Pegu, Lawrence Shapiro, Tatyana Gindin, Lisa Kueltzo
-
Publication number: 20240239864Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD22 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: February 16, 2022Publication date: July 18, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kazusa Ishii, Christian Hinrichs
-
Patent number: 12037607Abstract: Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.Type: GrantFiled: November 8, 2018Date of Patent: July 16, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Raul E. Vizcardo, Naritaka Tamaoki, Meghan L. Good, Nicholas P. Restifo
-
Publication number: 20240228657Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: ApplicationFiled: September 20, 2023Publication date: July 11, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Publication number: 20240209032Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: ApplicationFiled: January 10, 2024Publication date: June 27, 2024Applicant: The United State of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Publication number: 20240209302Abstract: Ex vivo analysis can be performed by mounting a portion of live tissue resected from a patient on a sample platform. Using the sample platform, the resected tissue portion can be positioned within a perfusion chamber. Perfusate is flowed through the perfusion chamber and into contact with the resected tissue portion such that diffusion of oxygen occurs between the perfusate and the resected tissue portion. During the flowing, the resected tissue portion maintains a competent immune system. Drugs can be added to the perfusate flow to ascertain the effect on the tissue. The sample platform is designed to be removable from the perfusion chamber for analysis of the tissue by imaging or other investigation techniques, for experimental treatment, or for any other purpose. After removal, the sample platform can be returned to the perfusion chamber for continued viability of the tissue.Type: ApplicationFiled: March 9, 2021Publication date: June 27, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Jonathan Matthew Hernandez, Thomas J. Pohida, Marcial Antonio Garmendia, Samantha Marilyn Ruff, Michael Martin Wach, Shreya Gupta, James McDonald, Kirsten Remmert, Alexander Joseph Rossi
-
Patent number: 12018045Abstract: Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, a method of inducing apoptosis in cancer cells in a mammal, and a method of treating prostate cancer in mammal in need thereof comprising administration of a compound described herein.Type: GrantFiled: March 6, 2019Date of Patent: June 25, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on Behalf of the University of ArizonaInventors: Thomas J. Sayers, Poonam Tewary, Leslie Gunatilaka, Alan D. Brooks, Kithsiri Wijeratne, Yaming Xu
-
Patent number: 12018320Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: GrantFiled: February 18, 2022Date of Patent: June 25, 2024Assignees: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 12020494Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.Type: GrantFiled: November 9, 2022Date of Patent: June 25, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
-
Patent number: 12012455Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: GrantFiled: January 6, 2022Date of Patent: June 18, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
-
Patent number: 12011151Abstract: Among other things, there is disclosed structure and methods for maintaining access to a location in the body while reducing or eliminating the potential for pulling an access device (e.g. a catheter) back through an opening. An introducer sheath includes a distal indented portion and a balloon, so that once placed in a desired location through tissue, the balloon can be inflated to anchor the sheath against retraction. In particular embodiments, structure and methods for accessing the pericardial cavity via the right atrial appendage are shown.Type: GrantFiled: July 26, 2021Date of Patent: June 18, 2024Assignees: Muffin Incorporated, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Shaun Davis Gittard, Gregory James Hardy, John C. Sigmon, Jr., Jeremy T. Newkirk, William J. Havel, Neal E. Fearnot, Toby Rogers, Kanishka Ratnayaka, Robert L. Lederman
-
Patent number: 12012463Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.Type: GrantFiled: August 6, 2019Date of Patent: June 18, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Bryan D. Fleming
-
Publication number: 20240192226Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.Type: ApplicationFiled: January 16, 2024Publication date: June 13, 2024Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Publication number: 20240191284Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: ApplicationFiled: February 27, 2024Publication date: June 13, 2024Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 12005115Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: GrantFiled: July 7, 2020Date of Patent: June 11, 2024Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human ServicesInventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
-
Publication number: 20240181038Abstract: The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.Type: ApplicationFiled: March 25, 2022Publication date: June 6, 2024Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Ventzislav Bojidarov VASSILEV, Corey MALLETT, Ronan ROUXEL, Normand BLAIS, Masaru KANEKIYO, Barney S. GRAHAM
-
Patent number: 11999796Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding—transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: June 19, 2020Date of Patent: June 4, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Patent number: 11992523Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.Type: GrantFiled: June 27, 2022Date of Patent: May 28, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
-
Patent number: 11992519Abstract: A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.Type: GrantFiled: June 21, 2021Date of Patent: May 28, 2024Assignees: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, The United States Government as represented by the Department of Veterans AffairsInventors: Liyanage Parakrama Perera, Thomas Alexander Waldmann, Kevin Charles Conlon, Pin-Yu Perera
-
Publication number: 20240166637Abstract: The present invention is related to the development of novel compounds and methods for the treatment and/or prevention of malaria. The compounds prevent the formation by the malaria parasite of the plasmodium surface anion channel (PSAC) on the surface of the host cell. The compounds and methods described herein are effective against infection by a wide variety of Plasmodia strains known as the causative agent of malaria.Type: ApplicationFiled: January 21, 2022Publication date: May 23, 2024Applicants: Microbiotix, Inc., The United States Of America As Represented By The Secretary, Department of Health and Human ServiceInventors: Samanthi L. Waidyarachchi, Son T. Nguyen, Xiaoyuan Ding, Sharmila Adhikari, John D. Williams, Norton P. Peet, Zachary D. Aron, Sanjay A. Desai, Michelle M. Butler